Longeveron commenced treatment of first Left Heart Syndrome patient using mesenchymal stem cell therapy

Longeveron asserted that its revolutionary Clinical Trial initiated to treat infants with Hypoplastic Left Heart Syndrome as the first patient received the treatment using the company’s mesenchymal stem cell therapy in a procedure that was performed at the University of Maryland Medical C enter in Baltimore.

It is to be taken into account that Hypoplastic Left Heart Syndrome is a seldom and usually fatal condition caused by an underdeveloped heart. The Clinical trial certainly aims to ascertain if the stem cell treatment can enhance the ventricular function of the heart in afflicted infants.

Dr. Sunjay Kaushal, Director of Pediatric Cardiac Surgery at the University of Maryland. Dr. Kaushal performed the procedure claimed “The hope is the stem cell therapy available through this clinical trial will be a game-changer for these infants, an effective way to improve their outcomes and allow them to live longer lives.”

The Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome (ELPIS) is an open-label clinical trial enrolling 30 infants with HLHS. The study is a partnership between Longeveron, a Miami-based regenerative medicine company, the University of Maryland and Johns Hopkins University. The Maryland Stem Cell Research Fund (MSCRF) provided a $750,000 grant to support this groundbreaking stem cell research.